Lexaria Bioscience Corp. (LEXX) has released an update.
Lexaria Bioscience Corp. has received the green light from an ethics review board to proceed with a new pilot study testing their DehydraTECH technology with GLP-1 drugs in humans. The study will begin recruiting participants immediately, aiming to enhance the delivery and efficacy of the diabetes drug semaglutide while reducing side effects. Lexaria’s CEO expressed optimism that this innovation could significantly benefit the pharmaceutical industry and patients by providing a more tolerable and effective alternative to injections.
For further insights into LEXX stock, check out TipRanks’ Stock Analysis page.
